Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
AstraZeneca
Medtronic
Dow

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,879,842

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,879,842 protect, and when does it expire?

Patent 7,879,842 protects CORLANOR and is included in two NDAs.

Protection for CORLANOR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in forty-two countries.

Summary for Patent: 7,879,842
Title:Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Abstract: .beta.-Crystalline form of ivabradine of formula (I): ##STR00001## characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as bradycardics.
Inventor(s): Horvath; Stephane (La Chapelle-Saint-Mesmin, FR), Auguste; Marie-Noelle (Orleans, FR), Damien; Gerard (Meung-sur-Loire, FR)
Assignee: Les Laboratoires Servier (Suresnes Cedex, FR)
Application Number:12/589,283
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,879,842

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Amgen Inc CORLANOR ivabradine SOLUTION;ORAL 209964-001 Apr 22, 2019 RX Yes Yes   Start Trial   Start Trial Y Y A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE   Start Trial
Amgen Inc CORLANOR ivabradine hydrochloride TABLET;ORAL 206143-001 Apr 15, 2015 RX Yes No   Start Trial   Start Trial Y   Start Trial
Amgen Inc CORLANOR ivabradine hydrochloride TABLET;ORAL 206143-002 Apr 15, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,879,842

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France05 01985Feb 28, 2005

International Family Members for US Patent 7,879,842

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1907   Start Trial
Argentina 053147   Start Trial
Austria 407926   Start Trial
Australia 2006200856   Start Trial
Brazil PI0600623   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Dow
McKinsey
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.